Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Capricor Therapeutics Inc CAPR

Healthcare Biotechnology
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product... see more

NDAQ:CAPR - Post Discussion

Capricor Therapeutics Inc > Pfizer Phase III DMD Gene Therapy Study Misses Goal | Benzin
View:
Post by whytestocks on Jun 13, 2024 2:45pm

Pfizer Phase III DMD Gene Therapy Study Misses Goal | Benzin

Breaking News: $CAPR Pfizer Phase III DMD Gene Therapy Study Misses Goal | BenzingaPfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular...CAPR - Pfizer Phase III DMD Gene Therapy Study Misses Goal | Benzinga
Be the first to comment on this post
Capricor Therapeutics Inc